Foghorn Therapeutics (FHTX) Net Income towards Common Stockholders Growth (3y) (2022 - 2026)

Foghorn Therapeutics (FHTX) Net Income towards Common Stockholders Growth (3y) (2022 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income Growth (3y) (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - 84.25%
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - -10.84%
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn 26.38%
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - 34.98%
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -46.86%
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn 13.80%
9 Abivax 91.96 Bn 91.96 Bn - -
10 Foghorn Therapeutics 282.33 Mn 193.42 Mn - 13.36%

Historic Data

Download Data
DateValue
Mar 31, 2026 13.36%
Dec 31, 2025 8.45%
Sep 30, 2025 13.86%
Jun 30, 2025 11.73%
Mar 31, 2025 9.09%
Dec 31, 2024 11.89%
Sep 30, 2024 10.60%
Jun 30, 2024 1.10%
Mar 31, 2024 -1.94%
Dec 31, 2023 -4.54%
Sep 30, 2023 8.44%
Jun 30, 2023 -23.28%
Mar 31, 2023 -29.67%
Dec 31, 2022 -23.42%
Sep 30, 2022 -24.94%